行情

CNCE

CNCE

Concert Pharma
NASDAQ

实时行情|Nasdaq Last Sale

6.71
-0.16
-2.33%
盘后: 6.71 0 0.00% 16:41 11/15 EST
开盘
6.91
昨收
6.87
最高
7.02
最低
6.71
成交量
14.56万
成交额
--
52周最高
17.83
52周最低
5.36
市值
1.60亿
市盈率(TTM)
-2.0182
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CNCE 新闻

  • 汽油涨价引发大规模抗议 伊朗两天约千人被捕
  • 新浪美股.3小时前
  • 全球最大的IPO来了 沙特阿美IPO指导价敲定
  • 新浪财经综合.3小时前
  • 沙特阿美拟募资超240亿美元,整体估值达1.6万亿美元
  • 澎湃新闻.6小时前
  • 7000亿美元!金融业忽视女性每年付出的代价
  • 快科技.6小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

CNCE 简况

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
展开

Webull提供Concert Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。